To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

• Status: Active, not recruiting
• Trial end date: 2023-06-10
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the efficacy of four different drugs in combination for management of irritable bowel syndrome (IBS)-associated diarrhea. The main question to answer is:

• Is there a significant difference in effect of different drug combinations in management of irritable bowel syndrome with diarrhea?

Participants will be divided into 3 treatment groups.

• Each group will be given a combination of drugs for 2 weeks

• At the end of study, efficacy of different drug combinations and their potential side effects will be compared between the treatment groups

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bahria University
• Treatments: Alverine; Amitriptyline; Calcium polycarbophil; Mebeverine; Psyllium; Rifaximin

Criteria

Inclusion Criteria:

Individual of both gender between the age of 18-50 years Diagnosed case of Irritable Bowel Syndrome associated with Diarrhea

Exclusion Criteria:

• Presence of co morbid diseases

• Coronary Artery Disease (CAD)

• Chronic Obstructive Pulmonary Disease (COPD)

• Congestive Heart Failure (CHF)

• Patients taking drugs which modify or aggravate symptoms of IBS (antidepressants, calcium channel blockers etc.)

• Patients having hyperthyroidism & gluten hypersensitivity

• Patients with alarming symptoms, viz. history of fever, passage of blood in stool, loss of weight, any organic gastrointestinal disease in the recent past

• Patients with recent change in bowel habits, patients on any other concomitant medication for abdominal pain, bowel disturbance or altering gastrointestinal motility and malignancy of any other organ

• Patients with Irritable Bowel Disease and Celiac disease